Indication of Omalizumab for Chronic Urticaria Using the ‘Urticaria Control Test’ Instead of ‘Urticaria Activity Score’: Possible Impact for Health Systems
Actas Dermo-Sifiliográficas · 2024
DOI: 10.1016/j.ad.2022.10.044 ↗Kurz gefasst
Fallbericht in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von J Sánchez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Group of Clinical and Experimental Allergy, University of Antioquia, IPSU Clinic, Medellín, Colombia. Electronic address: jorgem.sanchez@udea.edu.co. Hauptthemen laut MEDLINE: Chronic Urticaria, Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Group of Clinical and Experimental Allergy, University of Antioquia, IPSU Clinic, Medellín, Colombia. Electronic address: jorgem.sanchez@udea.edu.co.
- Pharmacoeconomic Evaluation Group, SURA Company, Colombia.
- Group of Clinical and Experimental Allergy, University of Antioquia, IPSU Clinic, Medellín, Colombia.
Zitieren
APA
Sánchez, J., Alvarez, L., & López, J. F. (2024). Indication of Omalizumab for Chronic Urticaria Using the ‘Urticaria Control Test’ Instead of ‘Urticaria Activity Score’: Possible Impact for Health Systems. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2022.10.044
Vancouver
Sánchez J, Alvarez L, López JF. Indication of Omalizumab for Chronic Urticaria Using the ‘Urticaria Control Test’ Instead of ‘Urticaria Activity Score’: Possible Impact for Health Systems. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2022.10.044
BibTeX
@article{Snchez2024,
author = {Sánchez, J and Alvarez, L and López, J F},
title = {Indication of Omalizumab for Chronic Urticaria Using the ‘Urticaria Control Test’ Instead of ‘Urticaria Activity Score’: Possible Impact for Health Systems},
journal = {Actas Dermo-Sifiliográficas},
year = {2024},
doi = {10.1016/j.ad.2022.10.044}
}
EUVIMED